Q4 2024 Management View The company addressed its debt maturities by completing $1.8 billion in secured financings in 2024 and reducing total debt principal by nearly $200 million. This included ...

Business groups urged a U.S. judicial panel on Friday to reject a proposal to require more funding disclosures in ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...